efavaleukin alfa

Efavaleukin alfa is a novel recombinant fusion protein consisting of an interleukin 2 (IL-2) mutein fused to the C-terminal of an immunoglobulin G1 (IgG1) Fc domain via a synthetic linker. It is designed to selectively expand regulatory T cells (Treg) by preferentially binding to the high-affinity IL-2 receptor, which is constitutively expressed at high levels on Treg cells. This selective expansion leads to increased cell surface retention and sustained signaling in Tregs, with minimal effects on other immune cell populations such as conventional CD4+ T cells, CD8+ T cells, or NK cells. Efavaleukin alfa has demonstrated robust and prolonged dose-dependent expansion of functional regulatory T cell subsets in both healthy subjects and patients with systemic lupus erythematosus (SLE). The drug is being developed primarily for autoimmune diseases including SLE and ulcerative colitis. Amgen is the developer of efavaleukin alfa[1][2][3][5][6].

Other names

efavaleukin alfa